A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs
A drug is defined as highly variable if its intra-individual coefficient of variation (CV) is greater than or equal to 30%. In such a case, bioequivalence may be assessed by means of methods that take the (high) variability into account. The Scaled Average Bioequivalence (SABE) approach is such a pr...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 January 2018
|
| In: |
European journal of clinical pharmacology
Year: 2018, Jahrgang: 74, Heft: 5, Pages: 549-559 |
| ISSN: | 1432-1041 |
| DOI: | 10.1007/s00228-018-2415-7 |
| Online-Zugang: | Resolving-System, Volltext: https://doi.org/10.1007/s00228-018-2415-7 Verlag: https://link.springer.com/article/10.1007%2Fs00228-018-2415-7 
|
| Verfasserangaben: | Sophie I. E. Knahl, Benjamin Lang, Frank Fleischer, Meinhard Kieser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1682371395 | ||
| 003 | DE-627 | ||
| 005 | 20230428044106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191121s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-018-2415-7 |2 doi | |
| 035 | |a (DE-627)1682371395 | ||
| 035 | |a (DE-599)KXP1682371395 | ||
| 035 | |a (OCoLC)1341278466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Knahl, Sophie |e VerfasserIn |0 (DE-588)120012443X |0 (DE-627)1682372944 |4 aut | |
| 245 | 1 | 2 | |a A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs |c Sophie I. E. Knahl, Benjamin Lang, Frank Fleischer, Meinhard Kieser |
| 264 | 1 | |c 23 January 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.11.2019 | ||
| 520 | |a A drug is defined as highly variable if its intra-individual coefficient of variation (CV) is greater than or equal to 30%. In such a case, bioequivalence may be assessed by means of methods that take the (high) variability into account. The Scaled Average Bioequivalence (SABE) approach is such a procedure and represents the recommendations of FDA. The aim of this investigation is to compare the performance characteristics of classical group sequential designs (GSD) and fixed design settings for three-period crossover bioequivalence studies with highly variable drugs, where the SABE procedure is utilized. | ||
| 650 | 4 | |a Bioequivalence | |
| 650 | 4 | |a Group sequential designs | |
| 650 | 4 | |a Highly variable drugs | |
| 650 | 4 | |a Two-stage designs | |
| 700 | 1 | |a Kieser, Meinhard |d 1960- |e VerfasserIn |0 (DE-588)103276547X |0 (DE-627)739277766 |0 (DE-576)168963825 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d Berlin : Springer, 1968 |g 74(2018), 5, Seite 549-559 |h Online-Ressource |w (DE-627)253722829 |w (DE-600)1459058-X |w (DE-576)072372613 |x 1432-1041 |7 nnas |a A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs |
| 773 | 1 | 8 | |g volume:74 |g year:2018 |g number:5 |g pages:549-559 |g extent:11 |a A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00228-018-2415-7 |x Resolving-System |x Verlag |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007%2Fs00228-018-2415-7 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191121 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 103276547X |a Kieser, Meinhard |m 103276547X:Kieser, Meinhard |d 910000 |d 999701 |e 910000PK103276547X |e 999701PK103276547X |k 0/910000/ |k 1/910000/999701/ |p 4 |y j | ||
| 999 | |a KXP-PPN1682371395 |e 3543906585 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"language":["eng"],"part":{"year":"2018","text":"74(2018), 5, Seite 549-559","pages":"549-559","extent":"11","volume":"74","issue":"5"},"title":[{"title":"European journal of clinical pharmacology","title_sort":"European journal of clinical pharmacology"}],"note":["Gesehen am 11.10.05"],"origin":[{"publisher":"Springer","dateIssuedKey":"1968","dateIssuedDisp":"1968-","publisherPlace":"Berlin ; Heidelberg ; New York"}],"titleAlt":[{"title":"Clinical pharmacology"},{"title":"EJCP"},{"title":"Pharmacologia clinica"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugsEuropean journal of clinical pharmacology","id":{"issn":["1432-1041"],"eki":["253722829"],"zdb":["1459058-X"]},"recId":"253722829","pubHistory":["1.1968/69 -"],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["organ of European Association for Clinical Pharmacology and Therapeutics (EACPT)"]}}],"id":{"doi":["10.1007/s00228-018-2415-7"],"eki":["1682371395"]},"recId":"1682371395","name":{"displayForm":["Sophie I. E. Knahl, Benjamin Lang, Frank Fleischer, Meinhard Kieser"]},"physDesc":[{"extent":"11 S."}],"language":["eng"],"title":[{"title":"A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs","title_sort":"comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs"}],"note":["Gesehen am 20.11.2019"],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"23 January 2018"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Sophie","role":"aut","display":"Knahl, Sophie","family":"Knahl"},{"display":"Kieser, Meinhard","family":"Kieser","role":"aut","given":"Meinhard"}]} | ||
| SRT | |a KNAHLSOPHICOMPARISON2320 | ||